Navigation auf zora.uzh.ch
DDOS: due to massive botnet requests against our ‘Advanced Search’ we have restricted access to UZH (local and VPN). Thank you for your understanding.
Skaria, Tom; Wälchli, Thomas; Vogel, Johannes (2021). CGRP receptor antagonism in COVID-19: potential cardiopulmonary adverse effects. Trends in Molecular Medicine, 27(1):7-10.
Recently, the US FDA has authorized a drug repurposing trial with calcitonin gene-related peptide (CGRP) receptor antagonists to reduce lung inflammation in coronavirus 2019 (COVID-19). However, the well-established cardiopulmonary protective effects of CGRP raise concerns about the safety of antagonizing CGRP in COVID-19. Awareness regarding potential cardiopulmonary adverse effects may enable their early detection and prevent illness from worsening.
| Item Type: | Journal Article, refereed, original work |
|---|---|
| Communities & Collections: | 04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
04 Faculty of Medicine > Zurich Center for Integrative Human Physiology (ZIHP) 05 Vetsuisse Faculty > Veterinärwissenschaftliches Institut > Institute of Veterinary Physiology |
| Dewey Decimal Classification: | 570 Life sciences; biology |
| Scopus Subject Areas: | Life Sciences > Molecular Medicine
Life Sciences > Molecular Biology |
| Language: | English |
| Date: | January 2021 |
| Deposited On: | 26 Jan 2021 16:09 |
| Last Modified: | 07 Jun 2025 03:40 |
| Publisher: | Elsevier |
| ISSN: | 1471-4914 |
| OA Status: | Closed |
| Publisher DOI: | https://doi.org/10.1016/j.molmed.2020.10.005 |
| PubMed ID: | 33129692 |
Skaria, Tom